Hyperlipoproteinemia: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Tarek Nafee (talk | contribs) No edit summary |
||
Line 356: | Line 356: | ||
|} | |} | ||
==Diagnostic Approach== | |||
{{familytree/start}} | |||
{{familytree | | | | | | | | | A01 | | | | | |A01=Hyperlipidemia}} | |||
{{familytree | | | | | | | | | |!| | | | | | ||}} | |||
{{familytree | | | | | | | | | |!| | | | | | ||}} | |||
{{familytree | | | | | | | | | B01 |-|-|B02|-|-| B03 |B01= Triglycerides > 75<sup>th</sup> Percentile|B02= NO|B03= Type IIa}} | |||
{{familytree | | | | | | | | | |!| | | | | | ||}} | |||
{{familytree | | | | | | | | | |!| | | | | | ||}} | |||
{{familytree | | | | | | | | | C01 | | | | | |C01= YES}} | |||
{{familytree | | | | | | | | | |!| | | | | | ||}} | |||
{{familytree | | | | | | | | | |!| | | | | | ||}} | |||
{{familytree | | | | | | | | | D01 | | | | | |D01=Types I, IIb, IV, V }} | |||
{{familytree | | | | | | | | | |!| | | | | | ||}} | |||
{{familytree | | | | | | | | | |!| | | | | | ||}} | |||
{{familytree | | | | | | | | | E01 |-|-|E02|-|-| E03 |E01= Total Cholesterol/Apo B ratio ≥ 6.2 |E02=NO|E03= Types IIb, IV }} | |||
{{familytree | | | | | | | | | |!| | | | | | ||}} | |||
{{familytree | | | | | | | | | |!| | | | | | ||}} | |||
{{familytree | | | | | | | | | F01 | | | | | |F01= YES}} | |||
{{familytree | | | | | | | | | |!| | | | | | ||}} | |||
{{familytree | | | | | | | | | |!| | | | | | ||}} | |||
{{familytree | | | | | | | | | G01 | | | | | |G01=Types I, III, V }} | |||
{{familytree | | | | | | | | | |!| | | | | | ||}} | |||
{{familytree | | | | | | | | | |!| | | | | | ||}} | |||
{{familytree | | | | | | | | | H01 |-|-|H02|-|-| H03 |H01= Triglycerides/Apo B ratio < 10.0 |H02=NO|H03= Types I, V }} | |||
{{familytree | | | | | | | | | |!| | | | | | ||}} | |||
{{familytree | | | | | | | | | |!| | | | | | ||}} | |||
{{familytree | | | | | | | | | I01 | | | | | |I01= YES}} | |||
{{familytree | | | | | | | | | |!| | | | | | ||}} | |||
{{familytree | | | | | | | | | |!| | | | | | ||}} | |||
{{familytree | | | | | | | | | J01 | | | | | |J01= Type III}} | |||
{{familytree/end}} | |||
==References== | ==References== |
Revision as of 23:27, 8 November 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Classification
Hyperlipoproteinemia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Type I: Familial hyperchylomicronemia | Type II | Type III: Dysbetalipoproteinemia | Type IV: Primary hypertriglyceridemia | Type V: Mixed hyperlipoproteinemia | |||||||||||||||||||||||||||||||||||||||||||||||||||
Type A: Familial hypercholesterolemia | Type B: Familial combined hyperlipidemia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Synopsis
Hyperlipoproteinemia | Synonyms | Problems | Labs description | Treatment |
---|---|---|---|---|
Type I | Buerger-Gruetz syndrome, primary hyperlipoproteinaemia, or familial hyperchylomicronemia | Decreased lipoprotein lipase (LPL) or altered ApoC2 | Elevated chylomicrons | Diet control |
Type IIa | Polygenic hypercholesterolaemia or familial hypercholesterolemia | LDL receptor deficiency | Elevated LDL only | Bile acid sequestrants, statins, niacin |
Type IIb | Combined hyperlipidemia | Decreased LDL receptor and increased ApoB | Elevated LDL, VLDL and triglycerides | Statins, niacin, gemfibrozil |
Type III | Familial Dysbetalipoproteinemia | Defect in ApoE synthesis | Increased IDL | Drug of choice: Gemfibrozil |
Type IV | Endogenous Hyperlipemia | Increased VLDL production and decreased elimination | Increased VLDL | Drug of choice: Niacin |
Type V | Familial Hypertriglyceridemia | Increased VLDL production and decreased LPL | Increased VLDL and chylomicrons | Niacin, gemfibrozil |
Differential Diagnosis
Diseases | Mode of Inheritance | Laboratory Findings | Other Findings | Management | Complications | Prognosis | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lipid Profile | Other Laboratory Findings | |||||||||||||
Total Cholesterol | LDL | HDL | Triglycerides | Plasma Appearance | Chylomicrons | VLDL | Genetic mutations | |||||||
Primary Hyperlipoprotenemia | Type I | Autosomal Recessive
& Autosomal Dominant(Rare) |
Normal or ↑ | ↓ | ↓↓↓ | ↑↑↑↑ | Milky | ↑↑↑↑ | ↓ | -LPL gene mutation | -Fat tolerance markedly abnormal
-Carbohydrate inducibility may be abnormal |
Treatment for hyperlipoproteinemia type 1 is intended to control blood triglyceride levels with a very low-fat diet | -Recurrent Pancreatitis
-Rarely life threatening |
Good |
Type IIA | ||||||||||||||
Type IIB | ||||||||||||||
Type III | ||||||||||||||
Type IV | Autosomal Recessive
& Autosomal Dominant |
Normal or ↑ | Prebeta-HDL ↑
& HDL-C |
↑↑ | Clear or Cloudy | Normal | ↑ | -LPL genes (Gly188Glu,Asp9Asn, Asn291Ser,Ser447Ter)
-APOA5 -LMF1 -GPIHBP1 |
Hyperglycemia, Pancytopneia and pseudo-Niemann
pick cells |
-Weight reduction
-Fibrates -Gene therapy |
-Ischemic Heart Disea
-Recurrent Pancreatitis -NIDDM -NAFLD |
|||
Type V | ||||||||||||||
Secondary Hyperlipoprotenemia | Diabetes Mellitus | |||||||||||||
Alcohol Abuse | ||||||||||||||
Estrogen Therapy | ||||||||||||||
Glucocorticoid therapy | ||||||||||||||
Renal Disease | ||||||||||||||
Obesity | ||||||||||||||
High-fat diet | ||||||||||||||
Poor physical activity | ||||||||||||||
Paraproteinemic disorders | ||||||||||||||
Hypothyroidism |
Diagnostic Approach
Hyperlipidemia | |||||||||||||||||||||||||||||||||||||||||
Triglycerides > 75th Percentile | NO | Type IIa | |||||||||||||||||||||||||||||||||||||||
YES | |||||||||||||||||||||||||||||||||||||||||
Types I, IIb, IV, V | |||||||||||||||||||||||||||||||||||||||||
Total Cholesterol/Apo B ratio ≥ 6.2 | NO | Types IIb, IV | |||||||||||||||||||||||||||||||||||||||
YES | |||||||||||||||||||||||||||||||||||||||||
Types I, III, V | |||||||||||||||||||||||||||||||||||||||||
Triglycerides/Apo B ratio < 10.0 | NO | Types I, V | |||||||||||||||||||||||||||||||||||||||
YES | |||||||||||||||||||||||||||||||||||||||||
Type III | |||||||||||||||||||||||||||||||||||||||||